A Phase II, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects With Advanced Recurrent Ovarian Cancer (KEYNOTE-100)

Next Previous
Trial Profile

A Phase II, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects With Advanced Recurrent Ovarian Cancer (KEYNOTE-100)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Acronyms KEYNOTE-100
  • Sponsors Merck Sharp & Dohme

    • Most Recent Events

    • 19 Jan 2018 Results of an analysis of one patient enrolled at Yale university in this study reporting remarkable clinical response to pembrolizumab, published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 10 Jun 2017 Biomarkers information updated
    • 24 May 2017 Planned End Date changed from 7 Oct 2019 to 18 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top